Analyst Ratings For NASDAQ:NKTR – Nektar Therapeutics (NASDAQ:NKTR)
Today, JPMorgan Chase & Co. lowered its price target on NASDAQ:NKTR – Nektar Therapeutics (NASDAQ:NKTR) to per share.
Some recent analyst ratings include
- 4/20/2018-Seaport Global Securities initiated coverage with a Buy rating.
- 4/17/2018-Mizuho Reiterated Rating of Buy.
- 3/2/2018-Cowen Reiterated Rating of Buy.
Recent Insider Trading Activity For NASDAQ:NKTR – Nektar Therapeutics (NASDAQ:NKTR)
NASDAQ:NKTR – Nektar Therapeutics (NASDAQ:NKTR) has insider ownership of 4.31% and institutional ownership of 90.84%.
- On 5/16/2018 Gil M. Labrucherie, CFO, sold 4,941 with an average share price of $83.39 per share and the total transaction amounting to $412,029.99.
- On 5/16/2018 Howard W Robin, CEO, sold 12,791 with an average share price of $83.39 per share and the total transaction amounting to $1,066,641.49.
- On 5/16/2018 Jillian B. Thomsen, CAO, sold 3,576 with an average share price of $83.39 per share and the total transaction amounting to $298,202.64.
- On 5/16/2018 John Nicholson, COO, sold 4,917 with an average share price of $83.39 per share and the total transaction amounting to $410,028.63.
- On 5/16/2018 Stephen K Doberstein, SVP, sold 3,435 with an average share price of $83.39 per share and the total transaction amounting to $286,444.65.
- On 5/3/2018 Gil M. Labrucherie, CFO, sold 90,000 with an average share price of $84.05 per share and the total transaction amounting to $7,564,500.00.
- On 5/3/2018 Howard W Robin, CEO, sold 130,000 with an average share price of $84.05 per share and the total transaction amounting to $10,926,500.00.
Recent Trading Activity for NASDAQ:NKTR – Nektar Therapeutics (NASDAQ:NKTR)
Shares of NASDAQ:NKTR – Nektar Therapeutics closed the previous trading session at 54.97 down -35.38 39.16% with 54.849998474121094 shares trading hands.